Advertisement

Prospective Observational Study of a Racially Diverse Group of Men on Active Surveillance for Prostate Cancer

Published:November 06, 2020DOI:https://doi.org/10.1016/j.urology.2020.09.044

      Abstract

      Objective

      To evaluate the risk upgrading of active surveillance (AS), we reviewed the outcomes of African American men (AA) after electing AS. AS is the standard of care for men with low-grade prostate cancer (PCa). AA are known to have more advanced PCa features and are more likely to die from PCa, thus subsequent disease progression for AA on AS is unclear.

      Methods

      A prospectively maintained AS database from the Southeast Louisiana Veterans Administration Medical Center, New Orleans, Lousiana was queried. We identified men with low- and very low-risk PCa (Gleason 3 + 3, PSA <10, ≤CT2a) who had undergone at least 2 prostate biopsies, including initial diagnostic and subsequent confirmatory prostate biopsies. Descriptive and comparative statistical analysis was performed using R version 3.5.1.

      Results

      From a total of 274 men on AS (70% AA), 158 men met inclusion criteria (104 AA [66%]). All patients underwent at least 2 biopsies, and 29% underwent 3 or more biopsies. The median follow-up was 2.7 years. At 3 years on AS protocol, 57% AA and 61% Caucasians demonstrated no evidence of upgrading or treatment. No significant difference was observed between upgrading or progression to treatment when comparing racial groups. Seven (4%) patients in this cohort died from non PCa-specific causes, but no patients demonstrated metastasis or death from PCa over the course of study.

      Conclusion

      AA men with low-risk PCa can be safely followed with the same AS protocol as non-AA men. Further analysis with longer follow up is ongoing.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Jemal A
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30https://doi.org/10.3322/caac.21442
      1. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/prost.html. Published 2018. Accessed April 20, 2020.

        • Albertsen PC
        • Hanley JA
        • Fine J
        20-Year outcomes following conservative management of clinically localized prostate cancer.
        J Am Med Assoc. 2005; 293: 2095-2101https://doi.org/10.1001/jama.293.17.2095
        • Loeb S
        • Folkvaljon Y
        • Makarov DV
        • Bratt O
        • Bill-Axelson A
        • Stattin P
        Five-year nationwide follow-up study of active surveillance for prostate cancer.
        Eur Urol. 2015; 67: 233-238https://doi.org/10.1016/j.eururo.2014.06.010
        • Klotz L
        • Vesprini D
        • Sethukavalan P
        • et al.
        Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
        J Clin Oncol. 2015; 33: 272-277https://doi.org/10.1200/JCO.2014.55.1192
        • DeSantis CE
        • Siegel RL
        • Sauer AG
        • et al.
        Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities.
        CA Cancer J Clin. 2016; 66: 290-308https://doi.org/10.3322/caac.21340
        • Therneau TM
        • Grambsch PM
        Estimating the survival and hazard functions..
        Modeling Survival Data: Extending the Cox Model. Springer-Verlag, New York2000: 7-37https://doi.org/10.1007/978-1-4757-3294-8_2
        • Leapman MS
        • Freedland SJ
        • Aronson WJ
        • et al.
        Pathological and biochemical outcomes among African-American and caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy.
        J Urol. 2016; 196: 1408-1414https://doi.org/10.1016/j.juro.2016.06.086
        • Jalloh M
        • Myers F
        • Cowan JE
        • Carroll PR
        • Cooperberg MR
        Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
        Eur Urol. 2015; 67: 451-457https://doi.org/10.1016/j.eururo.2014.03.026
        • Resnick MJ
        • Canter DJ
        • Guzzo TJ
        • et al.
        Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy?.
        Urology. 2009; 73: 620-623https://doi.org/10.1016/j.urology.2008.09.035
        • Dall'Era MA
        • Cowan JE
        • Simko J
        • et al.
        Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
        BJU Int. 2011; 107: 1232-1237https://doi.org/10.1111/j.1464-410X.2010.09589.x
        • Hussein AA
        • Welty CJ
        • Ameli N
        • et al.
        Untreated gleason grade progression on serial biopsies during prostate cancer active surveillance: clinical course and pathological outcomes.
        J Urol. 2015; 194: 85-90https://doi.org/10.1016/j.juro.2015.01.077
        • Butler S
        • Muralidhar V
        • Chavez J
        • et al.
        Active surveillance for low-risk prostate cancer in black patients.
        N Engl J Med. 2019; 380: 2070-2072https://doi.org/10.1056/NEJMc1900333
        • Sundi D
        • Ross AE
        • Humphreys EB
        • et al.
        African American men with very low–risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?.
        J Clin Oncol. 2013; 31: 2991-2997https://doi.org/10.1200/JCO.2012.47.0302
        • Krishna S
        • Fan Y
        • Jarosek S
        • Adejoro O
        • Chamie K
        • Konety B
        Racial disparities in active surveillance for prostate cancer.
        J Urol. 2017; 197: 342-349https://doi.org/10.1016/j.juro.2016.08.104
        • Iremashvili V
        • Soloway MS
        • Rosenberg DL
        • Manoharan M
        Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance.
        J Urol. 2012; 187: 1594-1600https://doi.org/10.1016/j.juro.2011.12.082
        • Abern MR
        • Bassett MR
        • Tsivian M
        • et al.
        Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the duke prostate center.
        Prostate Cancer Prostatic Dis. 2013; 16: 84-89https://doi.org/10.1038/pcan.2012.38
        • Sundi D
        • Faisal FA
        • Trock BJ
        • et al.
        Reclassification rates are higher among African American men than Caucasians on active surveillance.
        Urology. 2015; 85: 155-160https://doi.org/10.1016/j.urology.2014.08.014
        • Odom BD
        • Mir MC
        • Hughes S
        • et al.
        Active surveillance for low-risk prostate cancer in African American men: a multi-institutional experience.
        Urology. 2014; 83: 364-368https://doi.org/10.1016/j.urology.2013.09.038
        • Schenk JM
        • Newcomb LF
        • Zheng Y
        • et al.
        African American race is not associated with risk of reclassification during active surveillance: results from the canary prostate cancer active surveillance study.
        J Urol. 2020; 203: 727-733https://doi.org/10.1097/ju.0000000000000621
        • Dess RT
        • Hartman HE
        • Mahal BA
        • et al.
        Association of black race with prostate cancer-specific and other-cause mortality.
        JAMA Oncol. 2019; 5: 975-983https://doi.org/10.1001/jamaoncol.2019.0826
        • Sundi D
        • Kryvenko ON
        • Carter HB
        • Ross AE
        • Epstein JI
        • Schaeffer EM
        Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.
        J Urol. 2014; 191: 60-66https://doi.org/10.1016/j.juro.2013.06.021
        • Tosoian JJ
        • Mamawala M
        • Epstein JI
        • et al.
        Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort.
        Eur Urol. 2020; 77: 675-682https://doi.org/10.1016/j.eururo.2019.12.017
        • Dall'Era MA
        • Konety BR
        • Cowan JE
        • et al.
        Active surveillance for the management of prostate cancer in a contemporary cohort.
        Cancer. 2008; 112: 2664-2670https://doi.org/10.1002/cncr.23502